Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CMMB
stocks logo

CMMB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.040
+25%
--
--
-0.040
+42.86%
--
--
-0.040
+150%
Estimates Revision
The market is revising No Change the revenue expectations for Chemomab Therapeutics Ltd. (CMMB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -20.06%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-20.06%
In Past 3 Month
Wall Street analysts forecast CMMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMMB is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CMMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMMB is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.470
sliders
Low
25.00
Averages
25.00
High
25.00
Current: 2.470
sliders
Low
25.00
Averages
25.00
High
25.00
Oppenheimer
Oppenheimer
Outperform
maintain
$10 -> $25
2025-08-27
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $25
2025-08-27
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Chemomab Therapeutics to $25 from $10 and keeps an Outperform rating on the shares to reflect Q2 results and management's intent to advance nebokitug in primary sclerosing cholangitis solely based on a third-party partnership, licensing or other similar transaction. The firm, which notes that its raised target reflects the potential value it sees to shareholders under an M&A or licensing scenario, points out that it also accounts for the company's 4-to-1 reverse share split.
Oppenheimer
Jeff Jones
Outperform
to
Outperform
downgrade
$11 -> $10
2025-05-16
Reason
Oppenheimer
Jeff Jones
Price Target
$11 -> $10
2025-05-16
downgrade
Outperform
to
Outperform
Reason
Oppenheimer analyst Jeff Jones lowered the firm's price target on Chemomab Therapeutics to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.
Maxim Group
Michael Okunewitch
Strong Buy
Maintains
$4 → $7
2025-02-20
Reason
Maxim Group
Michael Okunewitch
Price Target
$4 → $7
2025-02-20
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Chemomab Therapeutics Ltd (CMMB.O) is -15.44, compared to its 5-year average forward P/E of -34.88. For a more detailed relative valuation and DCF analysis to assess Chemomab Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-34.88
Current PE
-15.44
Overvalued PE
13.70
Undervalued PE
-83.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CMMB News & Events

Events Timeline

(ET)
2025-12-02
08:20:00
Chemomab Publishes Phase 2 SPRING Trial Results for PSC Treatment
select
2025-11-20 (ET)
2025-11-20
08:03:08
Chemomab Therapeutics Announces Q3 EPS of 0.4c Compared to (1c) Last Year
select
2025-11-06 (ET)
2025-11-06
08:40:31
Chemomab to Present Nebokitug Data at AASLD 2025
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-23NASDAQ.COM
Top Strong Buy Stocks for October 23: MQ, GES, and Others

  • Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.

  • Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.

  • Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.

  • Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.

[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

[object Object]
Preview
9.0
10-17NASDAQ.COM
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise

  • New Development Candidate: Esperion Therapeutics has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development aimed at treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no current approved treatments.

  • Market Potential and Financial Performance: If successful, ESP-2001 could tap into a market opportunity exceeding $1 billion annually, while Esperion's existing products, Nexletol and Nexlizet, have seen a 42% increase in U.S. sales, contributing to the company's growth amidst a rising stock price.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Chemomab Therapeutics Ltd (CMMB) stock price today?

The current price of CMMB is 2.47 USD — it has decreased -0.8 % in the last trading day.

arrow icon

What is Chemomab Therapeutics Ltd (CMMB)'s business?

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

arrow icon

What is the price predicton of CMMB Stock?

Wall Street analysts forecast CMMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMMB is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Chemomab Therapeutics Ltd (CMMB)'s revenue for the last quarter?

Chemomab Therapeutics Ltd revenue for the last quarter amounts to -2.26M USD, decreased -39.97 % YoY.

arrow icon

What is Chemomab Therapeutics Ltd (CMMB)'s earnings per share (EPS) for the last quarter?

Chemomab Therapeutics Ltd. EPS for the last quarter amounts to -3717000.00 USD, decreased -34.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for Chemomab Therapeutics Ltd (CMMB)'s fundamentals?

The market is revising No Change the revenue expectations for Chemomab Therapeutics Ltd. (CMMB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -20.06%.
arrow icon

How many employees does Chemomab Therapeutics Ltd (CMMB). have?

Chemomab Therapeutics Ltd (CMMB) has 16 emplpoyees as of December 05 2025.

arrow icon

What is Chemomab Therapeutics Ltd (CMMB) market cap?

Today CMMB has the market capitalization of 15.20M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free